Ibrutinib
BTK Inhibitor Challenges Standard of Care in Younger Patients With MCL
Already widely considered a standard first-line treatment in older adults with mantle cell lymphoma (MCL), a Bruton ...
JANUARY 11, 2023
Study Identifies Cardiovascular Toxicities Associated With Ibrutinib
The study identified several cardiovascular toxicities associated with ibrutinib, including supraventricular ...
SEPTEMBER 26, 2019
FDA Approves Imbruvica With Gazyva for First-Line CLL Treatment
The FDA expanded the labeling for Imbruvicato include use with Gazyva in treatment-naive patients with chronic ...
FEBRUARY 4, 2019
First-Line Ibrutinib-Based Rx More Effective, Less Toxic Than Standard for Younger CLL Patients
First-line treatment combining ibrutinib and rituximab (significantly improves progression-free survival and ...
JANUARY 17, 2019
Imbruvica Approved to Treat Waldenström Macroglobulinemia With Rituxan
The FDA approved the use of ibrutinib (Imbruvica, Pharmacyclics/Janssen) in combination with rituximab ...
AUGUST 30, 2018
